Insulet Reports Third Quarter 2026 Results
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Revenue $842.0 million, up 19.2%, slightly above high end of guidance
- ➤Adjusted EPS $1.99, up 59.9% year over year
- ➤International Omnipod revenue $266.2 million, up 31.7%
- ➤Board approved $1 billion share repurchase program; $400 million planned in Q4
- ➤FY 2026 total revenue growth guidance raised to 21%-22% from 20%-22%
Expert Statements
Ashley McEvoy, President and CEO of Insulet
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,”
Ashley McEvoy, President and CEO of Insulet
“We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation.”
Ashley McEvoy, President and CEO of Insulet
“As we look ahead, the business is well positioned for durable, profitable growth.”
Ashley McEvoy, President and CEO of Insulet
“The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.”
Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency(1))
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod(®) brand of products, today announced its financial results for the three months ended September 30, 2026.
Get started
Create a free account to read the full story.